WellDoc scores $22 million for BlueStar diabetes management platform

WellDoc, whose BlueStar technology is focused on adults with Type 2 diabetes, has drawn $22 million in a Series B round of funding from Samsung Ventures and existing investor Merck Global Health Innovation Fund. The company will use the money to continue commercialization and accelerate adoption of BlueStar.

Samsung and Excel will each provide one new member to the WellDoc board of directors.

BlueStar was cleared by the U.S. Food and Drug Administration for adults living with type 2 diabetes and their doctors. It requires a prescription from a licensed healthcare provider and can be dispensed by a pharmacy and reimbursed by a health plan. WellDoc's proprietary Automated Expert Analytics System powers BlueStar.

"The progress reported by those who have used BlueStar to date, and the data we have captured from that usage, motivates us to find new ways to make our product available to more people," said McRaith in a press statement. "With the financial contributions and strategic capabilities of the investors participating in our Series B, we can take WellDoc and BlueStar to the next level evolving our business model and distribution channels."